ZyVersa Therapeutics Revenue and Competitors

Weston, FL USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • ZyVersa Therapeutics's estimated annual revenue is currently $3M per year.(i)
  • ZyVersa Therapeutics's estimated revenue per employee is $201,000

Employee Data

  • ZyVersa Therapeutics has 15 Employees.(i)
  • ZyVersa Therapeutics grew their employee count by 15% last year.

ZyVersa Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder, Chairman and CEOReveal Email/Phone
2
CSO, Sr. VP R&DReveal Email/Phone
3
CMO and SVP Medical AffairsReveal Email/Phone
4
ControllerReveal Email/Phone
5
Chief Medical Officer Zyversa TherapeuticsReveal Email/Phone
6
Chief Commercial OfficerReveal Email/Phone
7
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.5M132N/AN/AN/A
#2
$10.1M5014%N/AN/A
#3
$282.6M1406N/AN/AN/A
#4
$13.9M6944%N/AN/A
#5
$11.3M564%N/AN/A
#6
$11.5M57-7%N/AN/A
#7
$211.7M10724%N/AN/A
#8
$24.1M1205%N/AN/A
#9
$7.8M39-2%N/AN/A
#10
$12.9M64-2%N/AN/A
Add Company

What Is ZyVersa Therapeutics?

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases with high unmet medical needs. Our clinical pipeline includes phase 2a VAR 200, an intracellular cholesterol efflux mediator for treatment of an orphan renal disease, focal segmental glomerulosclerosis (FSGS), and a novel inflammasome inhibitor with potential for multiple inflammatory diseases. VAR 200, 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), preclinical studies demonstrate that it promotes cholesterol removal from podocytes, the kidney's filtering system, slowing progression of podocyte injury and renal disease. Our novel inflammasome inhibitor targets the upstream innate immune system. It inhibits the ASC component of inflammasomes, blocking intracellular initiation of the inflammatory cascade and extracellular perpetuation of inflammation.

keywords:N/A

N/A

Total Funding

15

Number of Employees

$3M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.3M15-21%N/A
#2
$1.3M157%N/A
#3
$1.4M1678%N/A
#4
$1.3M1678%N/A
#5
N/A17-37%N/A